Maravai LifeSciences (MRVI) Competitors $2.43 -0.08 (-3.19%) Closing price 04:00 PM EasternExtended Trading$2.53 +0.10 (+4.07%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRVI vs. AMRX, CPRX, BHC, OGN, MIRM, XENE, IBRX, GMTX, ARWR, and APLSShould you be buying Maravai LifeSciences stock or one of its competitors? The main competitors of Maravai LifeSciences include Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), Bausch Health Cos (BHC), Organon & Co. (OGN), Mirum Pharmaceuticals (MIRM), Xenon Pharmaceuticals (XENE), ImmunityBio (IBRX), Gemini Therapeutics (GMTX), Arrowhead Pharmaceuticals (ARWR), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry. Maravai LifeSciences vs. Its Competitors Amneal Pharmaceuticals Catalyst Pharmaceuticals Bausch Health Cos Organon & Co. Mirum Pharmaceuticals Xenon Pharmaceuticals ImmunityBio Gemini Therapeutics Arrowhead Pharmaceuticals Apellis Pharmaceuticals Maravai LifeSciences (NASDAQ:MRVI) and AMNEAL PHARMACEUTICALS (NASDAQ:AMRX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk. Does the media refer more to MRVI or AMRX? In the previous week, Maravai LifeSciences and Maravai LifeSciences both had 2 articles in the media. AMNEAL PHARMACEUTICALS's average media sentiment score of 1.42 beat Maravai LifeSciences' score of 1.05 indicating that AMNEAL PHARMACEUTICALS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AMNEAL PHARMACEUTICALS 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is MRVI or AMRX more profitable? AMNEAL PHARMACEUTICALS has a net margin of -0.46% compared to Maravai LifeSciences' net margin of -67.14%. Maravai LifeSciences' return on equity of -12.91% beat AMNEAL PHARMACEUTICALS's return on equity.Company Net Margins Return on Equity Return on Assets Maravai LifeSciences-67.14% -12.91% -6.87% AMNEAL PHARMACEUTICALS -0.46%-188.26%5.34% Do analysts prefer MRVI or AMRX? Maravai LifeSciences currently has a consensus price target of $6.64, suggesting a potential upside of 173.21%. AMNEAL PHARMACEUTICALS has a consensus price target of $11.60, suggesting a potential upside of 45.55%. Given Maravai LifeSciences' higher possible upside, research analysts clearly believe Maravai LifeSciences is more favorable than AMNEAL PHARMACEUTICALS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maravai LifeSciences 1 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.25AMNEAL PHARMACEUTICALS 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, MRVI or AMRX? Maravai LifeSciences has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Comparatively, AMNEAL PHARMACEUTICALS has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Do insiders & institutionals have more ownership in MRVI or AMRX? 50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 31.8% of AMNEAL PHARMACEUTICALS shares are held by institutional investors. 2.1% of Maravai LifeSciences shares are held by company insiders. Comparatively, 26.6% of AMNEAL PHARMACEUTICALS shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has preferable earnings and valuation, MRVI or AMRX? AMNEAL PHARMACEUTICALS has higher revenue and earnings than Maravai LifeSciences. AMNEAL PHARMACEUTICALS is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaravai LifeSciences$259.18M2.39-$144.85M-$1.14-2.13AMNEAL PHARMACEUTICALS$2.79B0.89-$116.89M-$0.04-199.25 SummaryAMNEAL PHARMACEUTICALS beats Maravai LifeSciences on 11 of the 15 factors compared between the two stocks. Get Maravai LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRVI vs. The Competition Export to ExcelMetricMaravai LifeSciencesMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$639.20M$10.25B$5.54B$9.41BDividend YieldN/A2.06%3.75%4.03%P/E Ratio-2.1311.7121.0120.09Price / Sales2.3930.03433.8199.01Price / Cash4.0622.3936.1658.27Price / Book1.073.578.125.65Net Income-$144.85M$235.43M$3.25B$257.91M7 Day Performance-10.99%-1.67%0.97%2.09%1 Month Performance20.90%2.91%7.36%11.13%1 Year Performance-73.00%-16.44%31.31%18.40% Maravai LifeSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRVIMaravai LifeSciences3.5373 of 5 stars$2.43-3.2%$6.64+173.2%-73.0%$639.20M$259.18M-2.13610Positive NewsAMRXAmneal Pharmaceuticals3.2298 of 5 stars$8.41-0.1%$11.60+37.9%+10.9%$2.64B$2.79B-210.208,100News CoverageCPRXCatalyst Pharmaceuticals4.8975 of 5 stars$20.95-2.4%$32.83+56.7%+26.9%$2.56B$491.73M13.3480Positive NewsBHCBausch Health Cos3.7223 of 5 stars$6.88-2.5%$7.42+7.8%-14.9%$2.55B$9.63B-62.5520,700OGNOrganon & Co.4.8601 of 5 stars$9.74-2.2%$18.00+84.8%-54.4%$2.53B$6.29B3.384,000Trending NewsMIRMMirum Pharmaceuticals3.7678 of 5 stars$50.47+0.3%$65.50+29.8%+37.4%$2.50B$379.25M-31.35140News CoverageXENEXenon Pharmaceuticals3.4615 of 5 stars$31.83-4.3%$54.82+72.2%-23.7%$2.44B$9.43M-9.85210Positive NewsIBRXImmunityBio2.2868 of 5 stars$2.72flat$12.25+350.4%-53.8%$2.40B$31.22M-4.69590Gap UpGMTXGemini TherapeuticsN/A$54.75+3.0%N/A+19.7%$2.37BN/A-54.7530ARWRArrowhead Pharmaceuticals3.8607 of 5 stars$16.84+0.3%$43.71+159.6%-32.7%$2.33B$3.55M-12.03400News CoveragePositive NewsAPLSApellis Pharmaceuticals4.3305 of 5 stars$17.42-4.6%$39.79+128.4%-49.3%$2.19B$781.37M-9.73770Trending NewsAnalyst ForecastInsider TradeAnalyst Revision Related Companies and Tools Related Companies AMRX Alternatives CPRX Alternatives BHC Alternatives OGN Alternatives MIRM Alternatives XENE Alternatives IBRX Alternatives GMTX Alternatives ARWR Alternatives APLS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRVI) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maravai LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRVI Stock Alerts